FDA Grants AT-007 Pediatric Rare Disease Designation and Orphan Designation for treatment of PMM2-CDG

▴ FDA Grants AT-007 Pediatric Rare Disease Designation and Orphan Designation for treatment of PMM2-CDG
PMM2-CDG is a debilitating rare disease causes multiple organ failure and severe disability, resulting in approximately 20% mortality in the first four years of life

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has granted AT-007 both Pediatric Rare Disease Designation and Orphan Drug Designation for treatment of PMM2-CDG. PMM2-CDG is a debilitating rare disease caused by a deficiency in the critical enzyme phosphomannomutase-2, required for systemic glycosylation of proteins. PMM2-CDG causes multiple organ failure and severe disability, resulting in approximately 20% mortality in the first four years of life. There are currently no drugs approved to treat PMM2-CDG.

AT-007, a novel CNS penetrant Aldose Reductase inhibitor (recently given the INN scientific name gavorestat) has demonstrated biological activity in a validated model of PMM2-CDG. Applied Therapeutics plans to initiate a clinical study in 2021 and is currently working with CDG experts and the FDA to design a robust clinical program.

“PMM2-CDG is a debilitating disease with no drugs available, which is central to Applied Therapeutics’ mission of creating life-changing treatments for patients who desperately need them,” said Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics. “Over the past year we have been working closely with clinicians, researchers and families of PMM2-CDG patients, and are grateful for their collaboration and support. We are pleased that the FDA recognizes the transformative potential of AT-007 in treating patients with PMM2-CDG.”

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, AT-007, is a novel central nervous system penetrant aldose reductase inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia and PMM2-CDG. The Company initiated a Galactosemia clinical program in June 2019, read out positive data in adult Galactosemia patients in April 2020, and commenced a pediatric Galactosemia study in June 2020. Applied plans to initiate a clinical study of AT-007 in PMM2-CDG in 2021.

The Company is also developing AT-001, a novel potent ARI that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, fatal fibrosis of the heart. The Company initiated a Phase 3 registrational study in DbCM in September 2019. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy, as well as novel dual PI3k inhibitors in preclinical development for orphan oncology indications.

Tags : #AppliedTherapeutics #AT-007 #LatestFDAApprovalNewsSep26 #PMM2-CDG #OrphanOncology #Galactesomia #DiabeticRetinopathy #LatestNewsPharmaSep26 #DiabeticCardiomyopathy

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

To stay well during festive seasonOctober 21, 2020
The fastest growing and the most awarded Cath Lab of India in 2018 is bringing affordable and accessible healthcare available for cardiovascular diseases in India saOctober 21, 2020
ViiV healthcare development program on cabotegravir and rilivirine has no pandemic interruptionsOctober 21, 2020
No significant clinical benefit with Umifenovir addition in COVID-19 treatment: Glenmark clinical study October 21, 2020
India sustains the continued trend of consistent decline in Active CasesOctober 21, 2020
Lifeness Science Institute by Luke Coutinho Introduces Programmes in Integrative Nutrition and DieteticsOctober 21, 2020
Lifeness Science Institute by Luke Coutinho Introduces Programmes in Integrative Nutrition and DieteticsOctober 21, 2020
Haryana tops Anemia Mukt Bharat Index in countryOctober 21, 2020
Covid Update: Assam & OdishaOctober 21, 2020
BriaCell announces the overall breast cancer survival (OS) data of its lead product candidate, Bria-IMT™October 21, 2020
Teladoc Health Data Shows Broadening Mental Health Care DemandOctober 21, 2020
China vaccinated 60,000 people: Result awaited October 21, 2020
Lilly hires outside advisor for COVID drug plant problemsOctober 21, 2020
No Child Mothers, Accelerating the reduction of adolescent pregnancies on occasion of Adolescent Pregnancy Prevention Week October 21, 2020
Tyber Medical receives US FDA clearance on foot and ankle plating systemsOctober 21, 2020
Green tea and coffee connected to lower death risk in people with diabetesOctober 21, 2020
MEDICAL FESTIVAL ASIA: Events for the region’s medical and healthcare sectorOctober 21, 2020
Selecta Biosciences and Asklepios BioPharmaceutical receives US FDA approval for their gene therapyOctober 21, 2020
Astellas Pharma received US FDA approval for the treatment of primary mitochondrial myopathiesOctober 21, 2020
GSK presents positive clinical data on maternal and older adults RSV candidate vaccinesOctober 21, 2020